Ecteinascidin-Analog-1 is primarily investigated for its potential in cancer treatment. It shows promising activity against various types of tumors, particularly soft tissue sarcomas and ovarian cancer. The compound works by binding to the minor groove of DNA, disrupting the cell's ability to replicate and ultimately leading to cancer cell death. Its unique mechanism of action makes it a valuable candidate for further research in developing targeted therapies for resistant cancers. Additionally, studies are exploring its use in combination with other chemotherapeutic agents to enhance efficacy and reduce side effects.